TY - JOUR AU - Luchitskiy, V. Ye. AU - Luchitskiy, Ye. V. AU - Tronko, M. D. PY - 2016/06/08 Y2 - 2024/03/28 TI - TESTOSTERONE REPLACEMENT THERAPY IN MEN WITH TYPE 2 DIABETES AND FAILURE TESTOSTERONE SYNDROME JF - Problems of Endocrine Pathology JA - PEP VL - 56 IS - 2 SE - DO - 10.21856/j-PEP.2016.2.05 UR - https://www.jpep.endocrinology.org.ua/index.php/1/article/view/700 SP - 35-41 AB - <p>It was studied the influence of testosterone replacement therapy with prolonged action on the<br>functional state of the pituitary-genital system, clinical symptoms of androgendeficiency in patients<br>with type 2 diabetes (DMt2) with androgendeficiency. The study involved 35 male patients with DMt2<br>aged 39–72 years, duration of diabetes 2–14 years and total testosterone (T) levels &lt; 10.4 nmol/l.<br>For the purpose of replacement testosterone treatment was used (1000 mg) of the oil solution of<br>testosterone undecanoate. After 3 and 6 months after initiation of treatment there was a significant<br>increase in total testosterone concentration 14.6 ± 0.9 nmol/l and 17.0 ± 0.7 nmol/l, respectively vs<br>8.3 ± 0.5 nmol/l before treatment (p &lt; 0.05). Changes in the average levels of estradiol and lutropin<br>during treatment were not observed. No clinically significant side effects were not detected. Taking<br>long-acting testosterone undecanoate injection led to normalization of the total testosterone levels<br>and improve erectile function in men with type 2 diabetes and androgendeficiency.</p> ER -